АЖУРИРАЊЕ Хематологија / Онкологија 2024 година
Конгрес на ЕСМО 2023 година
Patients with metastatic or inoperable breast cancer benefit from antibody-drug conjugates. Amivantamab combinations are emerging as new options for EGFR mutated advanced NSCLC. Datopotamab deruxtecan achieved the PFS endpoint for previously treated NSCLC. 177Lu PSMA-617 increases rPFS for metastatic castration resistant prostate cancer patients who are taxane naive. Digital health technologies are revolutionising cancer care.
Користите многу стара верзија на прелистувачот. Некои од функциите на оваа страница може да не се прикажуваат правилно.
МИНИМАЛНИ барања: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15-18, Apple Safari 7, SeaMonkey 2.15-2.23.
Meeting Resources19 Oct 2023OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts, ePosters, and more.Access to resources.
OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.
Daily ReporterPatients with metastatic or inoperable breast cancer can benefit from antibody-drug conjugates.23 Oct 2023Datopotamab Deruxtecan and Trastuzumab Deruxtecan Shown to Be Effective in Breast Cancer with HER2-non-Amplification.
Datopotamab Deruxtecan and Trastuzumab Deruxtecan Shown to Be Effective in Breast Cancer with HER2-Non-Amplification.
Daily ReporterCombination therapies with amivantamab are now available for advanced NSCLC mutated by EGFR.23 Oct 2023The MARIPOSA-2 and MARIPOSA phase III trials reported clinically meaningful improvements in first and second-line treatment compared to standard care.
Регистрирајте се за билети или штандови
Карта на место и хотели наоколу
Минхен - Холидеј Ин Минхен - Центар на градот, Баварија, Германија Минхен - Холидеј Ин Минхен - Центар на градот, Баварија, Германија
Зачленете се